GleamWall
中文EN

STEK Stemtech Corp

Wholesale-Drugs, Proprietaries & Druggists' Sundries · OTC · SEC CIK 1511820 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-50.9%
TTM net income YoY-18.7%
TTM EPS YoY100.0%
Revenue 3-yr CAGR-26.6%
Net income 3-yr CAGR—

Margins

Gross margin75.7%
Operating margin-134.0%
Net margin-191.3%
FCF margin-35.5%
EBITDA margin-124.8%

Returns

ROE—
ROA-102.2%
ROIC (approx.)—
Asset turnover0.53x

Leverage & solvency

Liabilities / assets361.0%
Debt / equity—
Current ratio0.05x
Interest coverage-2.62x

Cash quality & payout

Operating cash flow / net income0.19x
Accruals ratio-83.2%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$282,484$629,312$462,957$458,109$852,300$697,925$868,046$1.31M
Cost of revenue$68,914$163,639$109,304$103,432$169,817$145,909$147,782$268,593
Gross profit$213,570$465,673$353,653$354,677$682,483$552,016$720,264$1.05M
R&D expense$0$0$0$0$0$0$0$0
SG&A expense$539,193$539,719$1.40M$1.25M$882,435$697,987$1.73M$1.09M
Operating income-$371,398-$125,567-$1.09M-$863,937-$339,217-$300,988-$1.20M$33,163
Interest expense$109,526$112,734$97,659$618,356$508,699$79,727$245,368$537,503
Pretax income-$478,575-$292,358-$1.25M-$1.48M-$812,541-$296,280-$1.46M-$396,580
Income tax$0$0$0$0$0$0$0$0
Net income-$478,575-$292,358-$1.25M-$1.48M-$809,406-$293,145-$1.46M-$396,580
EBITDA-$329,525-$83,694-$1.05M-$822,072-$297,340-$259,111-$1.16M$218,160
EPS (basic)0.000.000.00—-0.010.00-0.01—
EPS (diluted)0.000.000.00—-0.010.00-0.01—
Weighted avg. shares (diluted)2.96B2.08B812.14M—150.10M142.44M118.70M—
Balance sheet
Cash & equivalents$255,555$246,772$256,149$238,245$255,416$272,450$305,836$255,298
Inventory$296,320$311,277$325,700$217,338$234,614$274,807$188,400$197,355
Current assets$558,275$571,233$602,589$457,062$1.02M$1.10M$936,079$921,746
PP&E, net$0—$0$0———$0
Goodwill$467,409$467,409$467,409$467,409$467,409$467,409$467,409$467,409
Intangibles$2.08M$2.12M$2.17M$2.21M$2.25M$2.29M$2.33M$2.38M
Total assets$3.11M$3.16M$3.25M$3.15M$3.76M$3.87M$3.75M$3.78M
Current liabilities$11.22M$11.11M$11.06M$10.59M$10.30M$10.32M$9.44M$8.74M
Short-term debt$132,822———————
Long-term debt$4.54M$4.40M$4.16M$4.16M$4.12M$4.14M$4.16M$3.82M
Total debt$4.68M$4.40M$4.16M$4.16M$4.12M$4.14M$4.16M$3.82M
Total liabilities$11.22M$11.11M$11.06M$10.59M$10.30M$10.32M$9.44M$8.74M
Shareholders' equity-$7.63M-$7.47M-$7.33M-$6.96M-$5.80M-$5.71M-$4.94M-$4.48M
Net debt$4.42M$4.15M$3.90M$3.92M$3.87M$3.87M$3.86M$3.56M
Shares outstanding3.00B2.74B1.65B425.98M158.89M142.44M142.44M135.76M
Cash flow statement
Operating cash flow-$296,392-$54,844-$425,883$127,001$24,971$74,952-$710,507-$270,920
Capital expenditure$0$0$0$0$0$0$0$0
Free cash flow-$296,392-$54,844-$425,883$127,001$24,971$74,952-$710,507-$270,920
Investing cash flow$0$0$0$0$0$0$0$0
Financing cash flow$117,979$200,155-$22,839$69,424-$161,548$473,380$78,754$1.01M
Depreciation & amortization$41,873$41,873$41,873$41,865$41,877$41,877$41,876$184,997
Stock-based compensation$110,665$109,463$108,260$110,666$110,666$109,462$108,260$209,060

Free plan shows the latest 8 periods; Pro shows all 61 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.